Manara - Qatar Research Repository
Browse
DOCUMENT
10.3389_fonc.2022.961086.pdf (10.48 MB)
DOCUMENT
supp_DataSheet_1_The burden of prostate cancer in North Africa and Middle East, 1990–2019_ Findings from the global burden of disease study.pdf (401.48 kB)
DOCUMENT
supp_DataSheet_2_The burden of prostate cancer in North Africa and Middle East, 1990–2019_ Findings from the global burden of disease study.docx (19.3 kB)
1/0
3 files

The burden of prostate cancer in North Africa and Middle East, 1990–2019: Findings from the global burden of disease study

journal contribution
submitted on 2024-04-17, 07:06 and posted on 2024-04-22, 11:18 authored by Mohsen Abbasi-Kangevari, Sahar Saeedi Moghaddam, Seyyed-Hadi Ghamari, Mohammadreza Azangou-Khyavy, Mohammad-Reza Malekpour, Negar Rezaei, Nazila Rezaei, Ali-Asghar Kolahi, Erfan Amini, Ali H. Mokdad, Hamidreza Jamshidi, Mohsen Naghavi, Bagher Larijani, Farshad Farzadfar, GBD 2019 NAME Prostate Cancer Collaborators, Hanadi Al Hamad, Brijesh Sathian, Mowafa Househ

Background

Prostate cancer (PCa) is the second most prevalent cancer among men worldwide. This study presents estimates of PCa prevalence, incidence, death, years-of-life-lost (YLLs), years-lived-with-disability (YLDs), disability-adjusted-life-years (DALYs), and the burden attributable to smoking during 1990-2019 in North Africa and Middle East using data of Global Burden of Diseases (GBD) Study 2019.

Methods

This study is a part of GBD 2019. Using vital registration and cancer registry data, the estimates on PCa burden were modeled. Risk factor analysis was performed through the six-step conceptual framework of Comparative Risk Assessment.

Results

The age-standardized rates (95% UI) of PCa incidence, prevalence, and death in 2019 were 23.7 (18.5-27.9), 161.1 (126.6-187.6), and 11.7 (9.4-13.9) per 100,000 population. While PCa incidence and prevalence increased by 77% and 144% during 1990-2019, respectively, the death rate stagnated. Of the 397% increase in PCa new cases, 234% was due to a rise in the age-specific incidence rate, 79% due to population growth, and 84% due to population aging. The YLLs, YLDs, and DALYs of PCa increased by 2% (-11.8-23.1), 108% (75.5-155.1), and 6% (-8.9-28.1). The death rate and DALYs rate attributable to smoking have decreased 12% and 10%, respectively. The DALYs rate attributable to smoking was 37.4 (15.9-67.8) in Lebanon and 5.9 (2.5-10.6) in Saudi Arabia, which were the highest and lowest in the region, respectively.

Conclusions

The PCa incidence and prevalence rates increased during 1990-2019; however, the death rate stagnated. The increase in the incidence was mostly due to the rise in the age-specific incidence rate, rather than population growth or aging. The burden of PCa attributable to smoking has decreased in the past 30 years.

Other Information

Published in: Frontiers in Oncology
License: https://creativecommons.org/licenses/by/4.0/
See article on publisher's website: https://dx.doi.org/10.3389/fonc.2022.961086

Additional institutions affiliated with: WHO Collaborating Center for Healthy Ageing and Dementia - HMC

History

Language

  • English

Publisher

Frontiers

Publication Year

  • 2022

License statement

This Item is licensed under the Creative Commons Attribution 4.0 International License.

Institution affiliated with

  • Hamad Medical Corporation
  • Rumailah Hospital - HMC
  • Hamad Bin Khalifa University
  • College of Science and Engineering - HBKU

Methodology

This study is a part of GBD 2019. Using vital registration and cancer registry data, the estimates on PCa burden were modeled. Risk factor analysis was performed through the six-step conceptual framework of Comparative Risk Assessment.

Geographic coverage

North Africa and Middle East

Usage metrics

    Hamad Medical Corporation

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC